(D)-Serine

(D)-Serine

SCHEMBL7446773

CNCC(=O)O.C[C@@H](N)C(=O)O.N[C@H](CO)C(=O)O

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.41
SLC1A1 P43005 4/20 0.38
BHMT Q93088 3/20 0.38
SLC1A3 P43003 4/20 0.37
SLC1A2 P43004 4/20 0.37
GRIK1 P39086 2/20 0.36
GRIA2 P42262 2/20 0.36
GRIA4 P48058 2/20 0.36
GRIK3 Q13003 2/20 0.36
GRIK5 Q16478 2/20 0.36
GRM8 O00222 1/20 0.36
GRM6 O15303 1/20 0.36
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36
GSR P00390 1/20 0.36
CYP1A2 P05177 1/20 0.36
GRM5 P41594 1/20 0.36
GRIA1 P42261 1/20 0.36
GRIA3 P42263 1/20 0.36
GRIN1 Q05586 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alanine SCHEMBL28294968 0.88 ALDH1A1 (0.40) SLC7A5SLC1A1BHMTSLC1A3SLC1A2
Alanine SCHEMBL11511190 0.88 ALDH1A1 (0.40) SLC7A5SLC1A1BHMTSLC1A3SLC1A2
Sarcosine SCHEMBL2368384 0.88 ALDH1A1 (0.40) SLC7A5SLC1A1BHMTSLC1A3SLC1A2
Sarcosine SCHEMBL17258535 0.84 ALDH1A1 (0.38) SLC7A5SLC1A1BHMTSLC1A3SLC1A2
Serine SCHEMBL1270313 0.84 SLC7A5 (0.54) SLC7A5SLC1A1BHMTSLC1A3SLC1A2
(D)-Serine SCHEMBL2029988 0.84 SLC7A5 (0.54) SLC7A5SLC1A1BHMTSLC1A3SLC1A2
Serine SCHEMBL17603642 0.84 SLC7A5 (0.54) SLC7A5SLC1A1BHMTSLC1A3SLC1A2
Serine SCHEMBL8679969 0.84 SLC7A5 (0.54) SLC7A5SLC1A1BHMTSLC1A3SLC1A2
Serine SCHEMBL1270317 0.84 SLC7A5 (0.54) SLC7A5SLC1A1BHMTSLC1A3SLC1A2
Serine SCHEMBL9448210 0.84 SLC7A5 (0.54) SLC7A5SLC1A1BHMTSLC1A3SLC1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1073432-A2 USE OF GLYCINE SITE AGONISTS OR GLYCINE UPTAKE INHIBITORS FOR TREATING NEUROPSYCHIATRIC DISORDERS THE GENERAL HOSPITAL CORPORATION (US) 2001-02-07 EP disclosed
WO-1999052519-A2 METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS THE GENERAL HOSPITAL CORPORATION (US) 1999-10-21 WO disclosed